Connors Investor Services’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Connors Investor Services’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-12,566	Closed	-$198K	–	162
2023 Q3	$198K	Buy	12,566 +2,500	+25%	+$44.9K	0.02%	138
2023 Q2	$196K	Buy	10,066 +3,000	+42%	+$71.2K	0.02%	149
2023 Q1	$200K	Hold	7,066	–	–	0.02%	152
2022 Q4	$207K	Buy	+7,066	New	+$225K	0.03%	143
2022 Q3	–	Sell	-6,066	Closed	-$270K	–	162
2022 Q2	$270K	Sell	6,066 -500	-8%	-$23K	0.03%	124
2022 Q1	$325K	Hold	6,566	–	–	0.03%	123
2021 Q4	$334K	Hold	6,566	–	–	0.03%	123
2021 Q3	$366K	Hold	6,566	–	–	0.04%	121
2021 Q2	$281K	Buy	+6,566	New	+$271K	0.03%	131
2021 Q1	–	Sell	-3,966	Closed	-$185K	–	176
2020 Q4	$185K	Buy	+3,966	New	+$185K	0.02%	139

Other funds holding EGRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Connors Investor Services's EGRX Position: Q4 2023 in Review

Connors Investor Services sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2023, closing a stake of 12,566 shares — an estimated $198K sold.

Connors Investor Services first reported a position in EGRX in Q4 2020 and held it in 10 quarters. The position peaked at $366K in Q3 2021. 104 funds tracked by Wall St. Rank hold EGRX as of Q4 2023.

Connors Investor Services reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
Connors Investor Services sold 12,566 Eagle Pharmaceuticals, Inc. shares in Q4 2023, an estimated $198K.
Connors Investor Services first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2020 and held it in 10 quarters.
Connors Investor Services's Eagle Pharmaceuticals, Inc. position peaked at $366K in Q3 2021.
104 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2023.

Based on Connors Investor Services's 13F filing for Q4 2023, filed 14 Feb 2024.